{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T04:27:24Z","timestamp":1793766444658,"version":"4.6.1"},"reference-count":89,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T00:00:00Z","timestamp":1793577600000},"content-version":"vor","delay-in-days":32,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008908","name":"University of Messina","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008908","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.clgc.2026.102644","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T06:06:16Z","timestamp":1785996376000},"page":"102644","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Detection of FGFR Alterations in Urothelial Carcinoma: Current Diagnostic Methodologies, Technical Considerations and Future Perspectives"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-1349-0910","authenticated-orcid":false,"given":"Gabriele","family":"Ricciardi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5638-0508","authenticated-orcid":false,"given":"Mariagiovanna","family":"Ballato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4957-3283","authenticated-orcid":false,"given":"Pietro","family":"Tralongo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1132-1761","authenticated-orcid":false,"given":"Vincenzo","family":"Fiorentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3478-9217","authenticated-orcid":false,"given":"Valeria","family":"Zuccal\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Fadda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6260-6310","authenticated-orcid":false,"given":"Maurizio","family":"Martini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.clgc.2026.102644_bib0001","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.2174\/1871520621666210121093852","article-title":"Erdafitinib as a novel and advanced treatment strategy of metastatic urothelial carcinoma","volume":"21","author":"Bansal","year":"2021","journal-title":"Anticancer Agents Med Chem"},{"issue":"7492","key":"10.1016\/j.clgc.2026.102644_bib0002","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature12965","article-title":"Comprehensive molecular characterization of urothelial bladder carcinoma","volume":"507","author":"Weinstein","year":"2014","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.clgc.2026.102644_bib0003","first-page":"545","article-title":"Treatment strategies for locally advanced and metastatic urothelial carcinoma based on molecular profiles: a review","volume":"41","author":"Hashimoto","year":"2026","journal-title":"Histol Histopathol"},{"issue":"5","key":"10.1016\/j.clgc.2026.102644_bib0004","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.clgc.2022.06.013","article-title":"Clinicopathological features of FGFR3 - mutated upper tract urothelial carcinoma: a genomic database analysis","volume":"20","author":"Rizzo","year":"2022","journal-title":"Clin Genitourin Cancer"},{"issue":"2","key":"10.1016\/j.clgc.2026.102644_bib0005","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1159\/000524989","article-title":"ANXA10 expression is inversely associated with tumor stage, grade, and TP53 expression in upper and lower urothelial carcinoma","volume":"90","author":"Kobayashi","year":"2023","journal-title":"Pathobiology"},{"issue":"5","key":"10.1016\/j.clgc.2026.102644_bib0006","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1590\/s1677-5538.ibju.2020.1006","article-title":"Simultaneous laparoscopic nephroureterectomy and robot-assisted anterior pelvic exenteration with intracorporeal ileal conduit urinary diversion: step-by-step video-illustrated technique","volume":"47","author":"Braz\u00e3o","year":"2021","journal-title":"Int Braz J Urol"},{"issue":"1","key":"10.1016\/j.clgc.2026.102644_bib0007","doi-asserted-by":"crossref","first-page":"23","DOI":"10.4103\/JIPO.JIPO_22_19","article-title":"Ramucirumab and docetaxel in patients with metastatic urothelial carcinoma harboring fibroblast growth factor receptor alterations: a case series and literature review","volume":"3","author":"Smith","year":"2020","journal-title":"J Immunother Precis Oncol"},{"issue":"43","key":"10.1016\/j.clgc.2026.102644_bib0008","doi-asserted-by":"crossref","DOI":"10.3346\/jkms.2024.39.e320","article-title":"FGFR inhibitors in urothelial cancer: from scientific rationale to clinical development","volume":"39","author":"Kwon","year":"2024","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.clgc.2026.102644_bib0009","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1258388","article-title":"Treatment approaches for FGFR-altered urothelial carcinoma: targeted therapies and immunotherapy","volume":"14","author":"Benjamin","year":"2023","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.clgc.2026.102644_bib0010","first-page":"326","article-title":"Clinical features of patients with MTAP-deleted bladder cancer","volume":"13","author":"De Souza","year":"2023","journal-title":"Am J Cancer Res"},{"issue":"7","key":"10.1016\/j.clgc.2026.102644_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2023.100151","article-title":"Frequent telomerase reverse transcriptase promoter and fibroblast growth factor receptor 3 mutations support the precursor nature of papillary urothelial hyperplasia of the urinary bladder","volume":"36","author":"Cheng","year":"2023","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.clgc.2026.102644_bib0012","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eururo.2024.08.033","article-title":"Tissue-based biomarkers steering clinical decisions in patients with urothelial cancer","volume":"87","author":"Afferi","year":"2025","journal-title":"Eur Urol"},{"issue":"34","key":"10.1016\/j.clgc.2026.102644_bib0013","doi-asserted-by":"crossref","first-page":"55924","DOI":"10.18632\/oncotarget.10482","article-title":"FGFR3-TACC3 fusion in solid tumors: mini review","volume":"7","author":"Costa","year":"2016","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.clgc.2026.102644_bib0014","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s12104-018-9814-7","article-title":"NMR backbone assignments of the tyrosine kinase domain of human fibroblast growth factor receptor 3 in apo state and in complex with inhibitor PD173074","volume":"12","author":"Sanfelice","year":"2018","journal-title":"Biomol NMR Assign"},{"issue":"4","key":"10.1016\/j.clgc.2026.102644_bib0015","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1534\/genetics.119.302345","article-title":"Fibroblast growth factor receptors function redundantly during zebrafish embryonic development","volume":"212","author":"Leerberg","year":"2019","journal-title":"Genetics"},{"issue":"6","key":"10.1016\/j.clgc.2026.102644_bib0016","doi-asserted-by":"crossref","DOI":"10.3390\/cells8060518","article-title":"Cancer mutations in FGFR2 prevent a negative feedback loop mediated by the ERK1\/2 pathway","volume":"8","author":"Szybowska","year":"2019","journal-title":"Cells"},{"issue":"5","key":"10.1016\/j.clgc.2026.102644_bib0017","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1021\/pr9010475","article-title":"Differential phosphoproteomics of fibroblast growth factor signaling: identification of Src family kinase-mediated phosphorylation events","volume":"9","author":"Cunningham","year":"2010","journal-title":"J Proteome Res"},{"issue":"12","key":"10.1016\/j.clgc.2026.102644_bib0018","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0003961","article-title":"Analysis of STAT1 activation by Six FGFR3 mutants associated with skeletal dysplasia undermines dominant role of STAT1 in FGFR3 signaling in cartilage","volume":"3","author":"Krejci","year":"2008","journal-title":"PLOS One"},{"issue":"4","key":"10.1016\/j.clgc.2026.102644_bib0019","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201708163","article-title":"An FGFR3\/MYC positive feedback loop provides new opportunities for targeted therapies in bladder cancers","volume":"10","author":"Mahe","year":"2018","journal-title":"EMBO Mol Med"},{"issue":"48","key":"10.1016\/j.clgc.2026.102644_bib0020","doi-asserted-by":"crossref","first-page":"4306","DOI":"10.1038\/onc.2009.280","article-title":"Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific manner","volume":"28","author":"di Martino","year":"2009","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.clgc.2026.102644_bib0021","article-title":"FGFR3b extracellular loop mutation lacks tumorigenicity in vivo but collaborates with p53\/pRB deficiency to induce high-grade papillary urothelial carcinoma","volume":"6","author":"Zhou","year":"2016","journal-title":"Sci Rep"},{"issue":"76","key":"10.1016\/j.clgc.2026.102644_bib0022","doi-asserted-by":"crossref","first-page":"34306","DOI":"10.18632\/oncotarget.26142","article-title":"Oncogenic driver FGFR3-TACC3 is dependent on membrane trafficking and ERK signaling","volume":"9","author":"Nelson","year":"2018","journal-title":"Oncotarget"},{"issue":"61","key":"10.1016\/j.clgc.2026.102644_bib0023","doi-asserted-by":"crossref","first-page":"102898","DOI":"10.18632\/oncotarget.22048","article-title":"Unique signalling connectivity of FGFR3-TACC3 oncoprotein revealed by quantitative phosphoproteomics and differential network analysis","volume":"8","author":"Lombardi","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.clgc.2026.102644_bib0024","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s42047-023-00142-0","article-title":"Molecular classification of high-grade, muscle-invasive urothelial carcinomas and the relationship with CTLA-4 and PD-L1 expression","volume":"6","author":"Pereira","year":"2023","journal-title":"Surg Exp Pathol"},{"issue":"1","key":"10.1016\/j.clgc.2026.102644_bib0025","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/sj.bjc.6606016","article-title":"Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo","volume":"104","author":"Lamont","year":"2011","journal-title":"Br J Cancer"},{"issue":"44","key":"10.1016\/j.clgc.2026.102644_bib0026","doi-asserted-by":"crossref","first-page":"71429","DOI":"10.18632\/oncotarget.12198","article-title":"Fibroblast growth factor receptor (FGFR) alterations in squamous differentiated bladder cancer: a putative therapeutic target for a small subgroup","volume":"7","author":"Baldia","year":"2016","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.clgc.2026.102644_bib0027","doi-asserted-by":"crossref","first-page":"736","DOI":"10.21037\/tau.2018.07.11","article-title":"The value of molecular markers in classification and prediction of progression in non-muscle-invasive bladder cancer","volume":"7","author":"Pan","year":"2018","journal-title":"Transl Androl Urol"},{"issue":"4","key":"10.1016\/j.clgc.2026.102644_bib0028","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/cjp2.167","article-title":"Greater utility of molecular subtype rather than epithelial-to-mesenchymal transition (EMT) markers for prognosis in high-risk non-muscle-invasive (HGT1) bladder cancer","volume":"6","author":"Ottley","year":"2020","journal-title":"J Pathol Clin Res"},{"issue":"1","key":"10.1016\/j.clgc.2026.102644_bib0029","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.eururo.2022.09.030","article-title":"FGFR3 mutational activation can induce luminal-like papillary bladder tumor formation and favors a male sex bias","volume":"83","author":"Shi","year":"2023","journal-title":"Eur Urol"},{"issue":"40","key":"10.1016\/j.clgc.2026.102644_bib0030","doi-asserted-by":"crossref","first-page":"25935","DOI":"10.18632\/oncotarget.25407","article-title":"Subclassification, survival prediction and drug target analyses of chemotherapy-na\u00efve muscle-invasive bladder cancer with a molecular screening","volume":"9","author":"Rinaldetti","year":"2018","journal-title":"Oncotarget"},{"issue":"16","key":"10.1016\/j.clgc.2026.102644_bib0031","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21165670","article-title":"Evolution of Urothelial Bladder Cancer in the Context of Molecular Classifications","volume":"21","author":"Minoli","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.clgc.2026.102644_bib0032","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s12894-018-0380-1","article-title":"Fibroblast growth factor receptor 3 (FGFR3) aberrations in muscle-invasive urothelial carcinoma","volume":"18","author":"Kim","year":"2018","journal-title":"BMC Urol"},{"issue":"4","key":"10.1016\/j.clgc.2026.102644_bib0033","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1002\/cam4.262","article-title":"FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder","volume":"3","author":"Guancial","year":"2014","journal-title":"Cancer Med"},{"issue":"5","key":"10.1016\/j.clgc.2026.102644_bib0034","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.3892\/ol.2015.3691","article-title":"Positive fibroblast growth factor receptor 3 immunoreactivity is associated with low-grade non-invasive urothelial bladder cancer","volume":"10","author":"Poyet","year":"2015","journal-title":"Oncol Lett"},{"issue":"5","key":"10.1016\/j.clgc.2026.102644_bib0035","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1369\/00221554221095530","article-title":"Immunohistochemical assays for bladder cancer molecular subtyping: optimizing parsimony and performance of lund taxonomy classifiers","volume":"70","author":"Hardy","year":"2022","journal-title":"J Histochem Cytochem"},{"issue":"1","key":"10.1016\/j.clgc.2026.102644_bib0036","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13073-019-0669-z","article-title":"Long non-coding RNAs identify a subset of luminal muscle-invasive bladder cancer patients with favorable prognosis","volume":"11","author":"de Jong","year":"2019","journal-title":"Genome Med"},{"key":"10.1016\/j.clgc.2026.102644_bib0037","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1590\/1806-9282.20220812","article-title":"The prognostic impact of tumor necrosis in non-muscle invasive bladder cancer","volume":"68","author":"Culpan","year":"2022","journal-title":"Rev Assoc Med Bras"},{"issue":"13","key":"10.1016\/j.clgc.2026.102644_bib0038","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14133256","article-title":"Intratumoral switch of molecular phenotype and overall survival in muscle invasive bladder cancer","volume":"14","author":"Carlo","year":"2022","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.clgc.2026.102644_bib0039","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2217\/fon-2023-0596","article-title":"Plain language summary of erdafitinib in locally advanced or metastatic urothelial carcinoma: a phase 2 study with long-term follow-up","volume":"20","author":"Loriot","year":"2024","journal-title":"Future Oncol"},{"key":"10.1016\/j.clgc.2026.102644_bib0040","article-title":"Safety and efficacy of the pan-FGFR inhibitor erdafitinib in advanced urothelial carcinoma and other solid tumors: a systematic review and meta-analysis","volume":"12","author":"Zheng","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.clgc.2026.102644_bib0041","article-title":"A Phase 3 study of erdafitinib compared with vinflunine or docetaxel or pembrolizumab in subjects with advanced urothelial cancer and selected FGFR gene aberrations","year":"2026","journal-title":"clinicaltrials.gov"},{"issue":"1","key":"10.1016\/j.clgc.2026.102644_bib0042","doi-asserted-by":"crossref","first-page":"1","DOI":"10.30699\/ijp.2020.124315.2357","article-title":"Pre-analytical practices in the molecular diagnostic tests, a concise review","volume":"16","author":"Sotoudeh Anvari","year":"2021","journal-title":"Iran J Pathol"},{"issue":"6","key":"10.1016\/j.clgc.2026.102644_bib0043","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.21037\/tau.2019.09.38","article-title":"Transurethral resection of bladder tumour (TURBT)","volume":"9","author":"Kim","year":"2020","journal-title":"Transl Androl Urol"},{"issue":"4","key":"10.1016\/j.clgc.2026.102644_bib0044","doi-asserted-by":"crossref","first-page":"540","DOI":"10.14744\/SEMB.2025.56244","article-title":"Evaluation of factors affecting transurethral bladder tumor resection quality: a single-center study including 1014 procedures","volume":"59","author":"Iplikci","year":"2025","journal-title":"Sisli Etfal Hospital Medical Bulletin"},{"issue":"2","key":"10.1016\/j.clgc.2026.102644_bib0045","doi-asserted-by":"crossref","DOI":"10.3390\/mps8020035","article-title":"The handling and sampling of radical cystectomy specimens: a standardized approach for pathological evaluation","volume":"8","author":"Sanguedolce","year":"2025","journal-title":"Methods Protoc"},{"issue":"4","key":"10.1016\/j.clgc.2026.102644_bib0046","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0196556","article-title":"Performance of next-generation sequencing on small tumor specimens and\/or low tumor content samples using a commercially available platform","volume":"13","author":"Morris","year":"2018","journal-title":"PLOS One"},{"key":"10.1016\/j.clgc.2026.102644_bib0047","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.00173","article-title":"Cold Formalin fixation guarantees DNA integrity in formalin fixed paraffin embedded tissues: premises for a better quality of diagnostic and experimental pathology with a specific impact on breast cancer","volume":"10","author":"Berrino","year":"2020","journal-title":"Front Oncol"},{"issue":"7","key":"10.1016\/j.clgc.2026.102644_bib0048","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0070714","article-title":"Quality control of RNA preservation and extraction from paraffin-embedded tissue: implications for RT-PCR and microarray analysis","volume":"8","author":"Kashofer","year":"2013","journal-title":"PLOS One"},{"issue":"1","key":"10.1016\/j.clgc.2026.102644_bib0049","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0016353","article-title":"Successful protein extraction from over-fixed and long-term stored formalin-fixed tissues","volume":"6","author":"Wolff","year":"2011","journal-title":"PLOS One"},{"issue":"9","key":"10.1016\/j.clgc.2026.102644_bib0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0203608","article-title":"Impact of storage conditions on the quality of nucleic acids in paraffin embedded tissues","volume":"13","author":"Groelz","year":"2018","journal-title":"PLOS One"},{"issue":"2","key":"10.1016\/j.clgc.2026.102644_bib0051","article-title":"Obtaining spatially resolved tumor purity maps using deep multiple instance learning in a pan-cancer study","volume":"3","author":"Oner","year":"2022","journal-title":"Patterns (N Y)"},{"issue":"1-2","key":"10.1016\/j.clgc.2026.102644_bib0052","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.cancergen.2015.12.004","article-title":"Digitally guided microdissection aids somatic mutation detection in difficult to dissect tumors","volume":"209","author":"Geiersbach","year":"2016","journal-title":"Cancer Genet"},{"issue":"12","key":"10.1016\/j.clgc.2026.102644_bib0053","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1038\/s41379-022-01161-0","article-title":"Artificial intelligence-augmented histopathologic review using image analysis to optimize DNA yield from formalin-fixed paraffin-embedded slides","volume":"35","author":"Osinski","year":"2022","journal-title":"Mod Pathol"},{"issue":"5","key":"10.1016\/j.clgc.2026.102644_bib0054","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1007\/s12094-022-03046-9","article-title":"New update to the guidelines on testing predictive biomarkers in non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology","volume":"25","author":"Isla","year":"2023","journal-title":"Clin Transl Oncol"},{"issue":"7","key":"10.1016\/j.clgc.2026.102644_bib0055","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14071795","article-title":"Molecularly targeted therapy towards genetic alterations in advanced bladder cancer","volume":"14","author":"Thomas","year":"2022","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.clgc.2026.102644_bib0056","doi-asserted-by":"crossref","DOI":"10.3390\/cancers18061026","article-title":"Pan-cancer targeted sequencing reveals genomic heterogeneity and prognostic subgroups in urothelial bladder cancer","volume":"18","author":"Ugrinovski","year":"2026","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.clgc.2026.102644_bib0057","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13051305","article-title":"FGFR3 Mutations in urothelial carcinoma: a single-center study using next-generation sequencing","volume":"13","author":"Yu","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.clgc.2026.102644_bib0058","article-title":"Fusion challenges in solid tumors: shaping the landscape of cancer care in precision medicine","volume":"8","author":"Ahmed","year":"2024","journal-title":"JCO Precis Oncol"},{"issue":"2","key":"10.1016\/j.clgc.2026.102644_bib0059","first-page":"142","article-title":"RT-PCR assay to detect FGFR3::TACC3 fusions in formalin-fixed, paraffin-embedded glioblastoma samples","volume":"11","author":"Priesterbach-Ackley","year":"2024","journal-title":"Neurooncol Pract"},{"issue":"2","key":"10.1016\/j.clgc.2026.102644_bib0060","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.euo.2025.07.005","article-title":"FGFR1\/3 signaling as an Achilles\u2019 heel of phenotypic diversity in urothelial carcinoma","volume":"9","author":"Pichler","year":"2026","journal-title":"Eur Urol Oncol"},{"issue":"14","key":"10.1016\/j.clgc.2026.102644_bib0061","doi-asserted-by":"crossref","first-page":"7898","DOI":"10.3390\/ijms23147898","article-title":"Prediction of response to cisplatin-based neoadjuvant chemotherapy of muscle-invasive bladder cancer patients by molecular subtyping including KRT and FGFR target gene assessment","volume":"23","author":"Ecke","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.clgc.2026.102644_bib0062","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.eururo.2024.09.012","article-title":"FGFR Inhibition in Urothelial Carcinoma","volume":"87","author":"Li","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2026.102644_bib0063","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.2147\/OTT.S318332","article-title":"Clinical evidence and selecting patients for treatment with erdafitinib in advanced urothelial carcinoma","volume":"15","author":"Sayegh","year":"2022","journal-title":"Onco Targets Ther"},{"issue":"7","key":"10.1016\/j.clgc.2026.102644_bib0064","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.urolonc.2021.01.025","article-title":"Fibroblast growth factor receptor: a systematic review and meta-analysis of prognostic value and therapeutic options in patients with urothelial bladder carcinoma","volume":"39","author":"Kardoust Parizi","year":"2021","journal-title":"Urol Oncol"},{"issue":"12","key":"10.1016\/j.clgc.2026.102644_bib0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0165109","article-title":"Development of RNA-FISH assay for detection of oncogenic FGFR3-TACC3 fusion genes in FFPE samples","volume":"11","author":"Kurobe","year":"2016","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.clgc.2026.102644_bib0066","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s00428-014-1672-9","article-title":"Increased angiogenesis and FGFR protein expression indicate a favourable prognosis in bladder cancer","volume":"465","author":"Bertz","year":"2014","journal-title":"Virchows Arch"},{"key":"10.1016\/j.clgc.2026.102644_bib0067","article-title":"Analyses of publicly available genomics resources define FGF-2-expressing bladder carcinomas as EMT-prone, proliferative tumors with low mutation rates and high expression of CTLA-4, PD-1 and PD-L1","volume":"2","author":"McNiel","year":"2017","journal-title":"Signal Transduct Target Ther"},{"issue":"13","key":"10.1016\/j.clgc.2026.102644_bib0068","doi-asserted-by":"crossref","first-page":"13858","DOI":"10.1021\/acs.jmedchem.5c00731","article-title":"LC-MF-4, a novel FGFR3 degrader for therapeutic intervention in FGFR3-altered cancers","volume":"68","author":"Zheng","year":"2025","journal-title":"J Med Chem"},{"issue":"5","key":"10.1016\/j.clgc.2026.102644_bib0069","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/s41379-020-00699-1","article-title":"Recurrent urothelial carcinoma-like FGFR3 genomic alterations in malignant Brenner tumors of the ovary","volume":"34","author":"Lin","year":"2021","journal-title":"Mod Pathol"},{"issue":"12","key":"10.1016\/j.clgc.2026.102644_bib0070","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1158\/1078-0432.CCR-16-2267","article-title":"A phase II trial of dovitinib in BCG-unresponsive urothelial carcinoma with FGFR3 mutations or overexpression: Hoosier Cancer Research Network Trial HCRN 12-157","volume":"23","author":"Hahn","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.clgc.2026.102644_bib0071","doi-asserted-by":"crossref","first-page":"O7","DOI":"10.1186\/1753-6561-3-S3-O7","article-title":"FGFR3 and TP53 mutations in urothelial cell carcinoma: two molecular pathways and diagnostic value","volume":"3","author":"Bakkar","year":"2009","journal-title":"BMC Proc"},{"key":"10.1016\/j.clgc.2026.102644_bib0072","first-page":"65","article-title":"Molecular grading of tumors of the upper urothelial tract using FGFR3 mutation status identifies patients with favorable prognosis","volume":"4","author":"Lyle","year":"2012","journal-title":"Res Rep Urol"},{"key":"10.1016\/j.clgc.2026.102644_bib0073","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211015499","article-title":"Erdafitinib treatment in Brazilian patients with metastatic urothelial carcinoma (mUC): real-world evidence from an expanded access program","volume":"13","author":"Monteiro","year":"2021","journal-title":"Ther Adv Med Oncol"},{"issue":"11","key":"10.1016\/j.clgc.2026.102644_bib0074","doi-asserted-by":"crossref","DOI":"10.1634\/theoncologist.2020-0334","article-title":"Fibroblast growth factor receptor (FGFR) inhibitors in urothelial cancer","volume":"25","author":"Garje","year":"2020","journal-title":"Oncologist"},{"issue":"9","key":"10.1016\/j.clgc.2026.102644_bib0075","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21093214","article-title":"Targeting the Src pathway enhances the efficacy of selective FGFR inhibitors in urothelial cancers with FGFR3 alterations","volume":"21","author":"Lima","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"12","key":"10.1016\/j.clgc.2026.102644_bib0076","doi-asserted-by":"crossref","first-page":"16541","DOI":"10.18632\/aging.203175","article-title":"Insights of fibroblast growth factor receptor 3 aberrations in pan-cancer and their roles in potential clinical treatment","volume":"13","author":"Li","year":"2021","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.clgc.2026.102644_bib0077","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.00955","article-title":"Erdafitinib antagonizes ABCB1-mediated multidrug resistance in cancer cells","volume":"10","author":"Feng","year":"2020","journal-title":"Front Oncol"},{"issue":"6","key":"10.1016\/j.clgc.2026.102644_bib0078","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12061366","article-title":"Erdafitinib resensitizes ABCB1-overexpressing multidrug-resistant cancer cells to cytotoxic anticancer drugs","volume":"12","author":"Wu","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.clgc.2026.102644_bib0079","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1186\/s12885-016-2570-0","article-title":"PIK3CA dependence and sensitivity to therapeutic targeting in urothelial carcinoma","volume":"16","author":"Ross","year":"2016","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.clgc.2026.102644_bib0080","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13073-017-0431-3","article-title":"Strategies for monitoring and combating resistance to combination kinase inhibitors for cancer therapy","volume":"9","author":"Ahronian","year":"2017","journal-title":"Genome Med"},{"issue":"21","key":"10.1016\/j.clgc.2026.102644_bib0081","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1111\/1759-7714.14656","article-title":"MET gene amplification is a mechanism of resistance to entrectinib in ROS1+ NSCLC","volume":"13","author":"Tyler","year":"2022","journal-title":"Thorac Cancer"},{"issue":"5","key":"10.1016\/j.clgc.2026.102644_bib0082","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/onc.2015.114","article-title":"Development of secondary mutations in wild-type and mutant EZH2 alleles cooperates to confer resistance to EZH2 inhibitors","volume":"35","author":"Gibaja","year":"2016","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.clgc.2026.102644_bib0083","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.21037\/tau-20-1259","article-title":"Toward urinary cell-free DNA-based treatment of urothelial carcinoma: a narrative review","volume":"10","author":"Hayashi","year":"2021","journal-title":"Transl Androl Urol"},{"issue":"13","key":"10.1016\/j.clgc.2026.102644_bib0084","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.7150\/jca.56779","article-title":"Regulatory region mutations of TERT, PLEKHS1 and GPR126 genes as urinary biomarkers in upper tract urothelial carcinomas","volume":"12","author":"Xing","year":"2021","journal-title":"J Cancer"},{"issue":"28","key":"10.1016\/j.clgc.2026.102644_bib0085","doi-asserted-by":"crossref","first-page":"42988","DOI":"10.18632\/oncotarget.8943","article-title":"Liquid biopsy monitoring uncovers acquired RAS-mediated resistance to cetuximab in a substantial proportion of patients with head and neck squamous cell carcinoma","volume":"7","author":"Braig","year":"2016","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.clgc.2026.102644_bib0086","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0232365","article-title":"Quantitative analysis of the BRAF V595E mutation in plasma cell-free DNA from dogs with urothelial carcinoma","volume":"15","author":"Tagawa","year":"2020","journal-title":"PLOS One"},{"issue":"7","key":"10.1016\/j.clgc.2026.102644_bib0087","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s00122-025-04948-2","article-title":"Integrating multi-omics and machine learning for disease resistance prediction in legumes","volume":"138","author":"Mohamedikbal","year":"2025","journal-title":"Theor Appl Genet"},{"issue":"5","key":"10.1016\/j.clgc.2026.102644_bib0088","doi-asserted-by":"crossref","DOI":"10.1093\/bioinformatics\/btae143","article-title":"Molecular mechanisms reconstruction from single-cell multi-omics data with HuMMuS","volume":"40","author":"Trimbour","year":"2024","journal-title":"Bioinformatics"},{"issue":"1","key":"10.1016\/j.clgc.2026.102644_bib0089","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13073-024-01282-y","article-title":"Spatial multi-omics: novel tools to study the complexity of cardiovascular diseases","volume":"16","author":"Kiessling","year":"2024","journal-title":"Genome Med"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326001448?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326001448?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T04:16:06Z","timestamp":1793765766000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767326001448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":89,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1558767326001448"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102644","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Detection of FGFR Alterations in Urothelial Carcinoma: Current Diagnostic Methodologies, Technical Considerations and Future Perspectives","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102644","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102644"}}